Drug news
NICE recommends Lixiana (edoxaban) for VTE- Daiichi Sankyo
The National Institute for Health and Care Excellence (NICE) has in draft guidance recommended Lixiana (edoxaban) from Daiichi Sankyo to treat and prevent the recurrence of deep vein thrombosis and pulmonary embolism (VTE).
Comment: Edoxaban has shown superiority in safety over warfarin by reduction of the risk of major bleeding. It is also attractive as it avoids the frequent checks required with warfarin and it causes less disruption to the daily lives of patients./p>
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.